| Name | Title | Contact Details |
|---|
Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing.
For thousands of years, people have discovered medicines from fungi by brewery. This approach has led to transformative medicines that saved millions of lives and have altered the course of medical history. Drug discovery by brewery proved to be difficult and time-consuming, leaving the field in search of a disruptive technological solution. Our genomically-enabled drug discovery engine is precisely that solution, dramatically accelerating the search for nature’s breakthrough drugs. At LifeMine, genomicists, bioinformaticians and microbiologists identify new evolutionary solutions for disease intervention; natural products chemists access the natural molecules that inspire our drug discovery efforts; biologist and chemist drug hunters craft these into disruptively innovative medicines, and translational medical scientists bring the life-saving solutions forward into patients in need.
Avantra Biosciences FKA Decision Biomarkers, Inc. is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Strive Compounding Pharmacy, were pioneering a movement in personalized medicine. Ditching the one-size-fits-all approach, we specialize in customizing medications to fit the unique health conditions and wellness goals of each individual. Our commitment to whole-person health is evident in our comprehensive services ranging from hormone replacement and weight management to dermatology and veterinary care. As a rapidly growing company, we pride ourselves on our robust company culture, strong partnerships with healthcare providers, and the effectiveness, safety, and benefits of our compounded drugs. Our pursuit of uncompromised excellence in compounding, coupled with a proactive approach to healthcare, sets us apart in creating healthier and happier lives, while also educating the world on the crucial role that compound pharmacies play within a healthy society.
Personalis, Inc. is partnering with biopharma to develop and commercialize the next generation of cancer immunotherapies. We provide advanced genomic sequencing and analytics for immuno-oncology. Our patented ACE (Accuracy and Content Enhanced) Technology forms the foundation of all Personalis products and makes it possible for us to achieve augmented coverage of difficult-to-sequence genomic regions often missed with the use of conventional sequencing techniques, for more comprehensive and accurate genomic data. ACE ImmunoID, our universal platform for immuno-oncology, combines augmented whole exome and transcriptome assays with analytics that capture neoantigens, elucidate the tumor microenviroment, and identify mechanisms of tumor escape.